PE-22-28
ResearchA novel synthetic peptide targeting TREK-1 potassium channels. Researched for rapid antidepressant effects with a unique mechanism distinct from SSRIs.
Mood & AnxietyCognitive EnhancementNeuroprotection
Half Life
Unknown
Time to Results
Days to weeks
Administration
SubQ injection, Nasal spray
🐾 Griffin's Research Scorecard
Research Strength
Human Data
Animal Data
Long-Term Data
Beginner Friendly
Storage Difficulty
Injection FrequencyVaries
Cost$$$
🐾 Griffin Says...
The antidepressant research space is exciting right now, and PE-22-28 offers a genuinely novel mechanism. TREK-1 channel inhibition is different from everything currently approved. Very early stage, but the concept is scientifically sound.
Benefits
- Antidepressant research potential
- Rapid onset vs traditional antidepressants
- Unique TREK-1 mechanism
- Cognitive protection
- Potential anxiety reduction
Best For
- Depression research
- Mood research
- Neurological health
Body Systems
Nervous System
Mechanisms of Action
- Inhibits TREK-1 potassium channels
- Modulates serotonergic neurotransmission
- Different pathway from SSRIs and SNRIs
Side Effects
| Effect | Frequency | Severity |
|---|---|---|
| Very limited safety data | Unknown | Unknown |
Contraindications
Antidepressant medications (unknown interactions), very limited data
Peptides discussed here are for research purposes only. Nothing on this page is medical advice. Always consult a qualified professional before making health decisions.
Ready to calculate your dose? Use Griffin's Peptide Calculator 🐾
Open Calculator